Musculoskeletal conditions are the focus of 2 new offerings from Priority Health for employers and the nationally recognized nonprofit's more than 1.3 million members.
Grand Rapids, Michigan — Sword Health's and Musculoskeletal (MSK) Centers of Excellence's care options for musculoskeletal conditions, hailed as both cost-effective and of high quality, will soon become available to employers to offer the more than 1.3 million members covered under a plan from Priority Health, the nationally recognized nonprofit.
From Sword Health, plan members and/or patients will be able to remotely access a proprietary AI platform for customized care options that best fit their needs, with services that include 24/7 help; this option has a target start date of November 1. And thanks to MSK Centers of Excellence, starting January 1, plan members will have access to reduced-cost care from 7 physician groups throughout Michigan renowned for their surgical results for treating 6 MSK conditions: total hip replacement, total knee replacement, lumbar fusion, lumbar laminectomy, cervical fusion and cervical laminectomy.
You can find out more by clicking here.
“Musculoskeletal conditions are among the most disabling conditions in the U.S. and one of the leading drivers of health care costs and lost productivity for employers and their employees,” said Rick Abbott, senior vice president of employer solutions for Priority Health. “We’re glad to offer these new services to help our members access high-quality, cost-effective and personalized care as part of our ongoing commitment to provide products that meet the diverse needs of our members.”
AI in Health Care: Balancing Governance, Innovation, and Trust
September 2nd 2025In this conversation with Reuben Daniel, associate vice president of artificial intelligence at UPMC Health Plan, we dive into how UPMC Health Plan builds trust with providers and members, discuss challenges of scaling AI effectively, and hear about concrete examples of AI's positive impact.
Listen
Impact of Amivantamab-Lazertinib on EGFR, MET Resistance Alterations in NSCLC: Danny Nguyen, MD
September 15th 2025The combination of amivantamab and lazertinib in first-line non–small cell lung cancer (NSCLC) significantly reduces resistance mechanisms with implications for second-line treatment, said Danny Nguyen, MD, of City of Hope.
Read More